Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
337.97
-2.84 (-0.83%)
At close: Nov 13, 2026, 4:00 PM EST
339.00
+1.03 (0.30%)
After-hours: Nov 13, 2026, 7:42 PM EST
CRL Revenue
Charles River Laboratories International had revenue of $982.73M in the quarter ending September 26, 2026, a decrease of -2.20%. This brings the company's total for the last twelve months to $3.98B, down -1.16% year-over-year. In the year 2025, Charles River Laboratories International had annual revenue of $4.02B, down -0.85%. That makes Charles River Laboratories International the 3,108th largest company in the world by revenue and 887th in the United States.
Revenue (ttm)
$3.98B
Revenue Growth
-1.16%
P/S Ratio
4.07
Revenue / Employee
$201,871
Employees
19,700
Market Cap
16.19B
Revenue by Segment
Fiscal year ended Dec 27, 2025 See the full CRL breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 27, 2025 | 4.02B | -34.61M | -0.85% |
| Dec 28, 2024 | 4.05B | -79.42M | -1.92% |
| Dec 30, 2023 | 4.13B | 153.35M | 3.86% |
| Dec 31, 2022 | 3.98B | 435.90M | 12.31% |
| Dec 25, 2021 | 3.54B | 616.23M | 21.08% |
| Dec 26, 2020 | 2.92B | 302.71M | 11.55% |
| Dec 28, 2019 | 2.62B | 355.13M | 15.67% |
| Dec 29, 2018 | 2.27B | 408.50M | 21.99% |
| Dec 30, 2017 | 1.86B | 176.17M | 10.48% |
| Dec 31, 2016 | 1.68B | 318.13M | 23.34% |
| Dec 26, 2015 | 1.36B | 65.64M | 5.06% |
| Dec 27, 2014 | 1.30B | 132.13M | 11.34% |
| Dec 28, 2013 | 1.17B | 36.00M | 3.19% |
| Dec 29, 2012 | 1.13B | -13.12M | -1.15% |
| Dec 31, 2011 | 1.14B | 9.23M | 0.81% |
| Dec 25, 2010 | 1.13B | -38.23M | -3.26% |
| Dec 26, 2009 | 1.17B | -123.66M | -9.55% |
| Dec 27, 2008 | 1.30B | 64.67M | 5.26% |
| Dec 29, 2007 | 1.23B | 172.24M | 16.27% |
| Dec 30, 2006 | 1.06B | 65.06M | 6.55% |
| Dec 31, 2005 | 993.33M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| IQVIA Holdings | 17.31B |
| Labcorp Holdings | 14.59B |
| Quest Diagnostics | 11.84B |
| ICON Public Limited Company | 8.23B |
| Illumina | 4.54B |
| Mettler-Toledo International | 4.20B |
| Revvity | 2.94B |
| Medpace Holdings | 2.84B |
CRL News
- 2 days ago - Charles River announces investments, enhancements across Microbial Solutions - TheFly
- 2 days ago - Charles River Strengthens Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability - Business Wire
- 2 days ago - Charles River, Toxys to broaden access to ToxTracker, ReproTracker - TheFly
- 3 days ago - Charles River price target raised to $388 from $325 at TD Cowen - TheFly
- 4 days ago - Tigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services Business - PRNewsWire
- 5 days ago - Charles River to acquire Frontage’s bioanalysis and DMPK businesses for $470M - TheFly
- 5 days ago - Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses - Business Wire
- 8 days ago - Charles River price target raised to $315 from $295 at Mizuho - TheFly